DiaSorin S.p.A. (DSRLF)
OTCMKTS · Delayed Price · Currency is USD
83.17
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
DiaSorin Revenue
DiaSorin had revenue of 280.00M EUR in the quarter ending September 30, 2025, a decrease of -2.44%. This brings the company's revenue in the last twelve months to 1.21B, up 2.65% year-over-year. In the year 2024, DiaSorin had annual revenue of 1.19B with 3.24% growth.
Revenue (ttm)
1.21B EUR
Revenue Growth
+2.65%
P/S Ratio
3.34
Revenue / Employee
368.73K EUR
Employees
3,280
Market Cap
4.74B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 37.22M | 3.24% |
| Dec 31, 2023 | 1.15B | -212.93M | -15.64% |
| Dec 31, 2022 | 1.36B | 123.48M | 9.98% |
| Dec 31, 2021 | 1.24B | 356.35M | 40.43% |
| Dec 31, 2020 | 881.31M | 174.99M | 24.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Global Cord Blood | 196.10M |
| Centogene | 53.65M |
| Bioqual | 46.54M |
| Interpace Biosciences | 41.92M |
| Psychemedics | 19.69M |
| China New Energy Group Company | 12.51M |
| Aspira Women's Health | 9.34M |
| Longduoduo Company | 2.72M |
DiaSorin News
- 3 months ago - DiaSorin S.p.A. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Diasorin SpA (FRA:34D) Q3 2025 Earnings Call Highlights: Navigating Growth Amidst Market Challenges - GuruFocus
- 3 months ago - Q3 2025 DiaSorin SpA Earnings Call Transcript - GuruFocus
- 3 months ago - Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning - Seeking Alpha
- 10 months ago - DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate - Seeking Alpha
- 11 months ago - DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 months ago - Italy's DiaSorin ex-Covid revenue in line with guidance - Reuters
- 1 year ago - Diagnostics group DiaSorin's nine-month adjusted core profit up 6% - Reuters